agent

(redirected from angiogenic gene therapy)
Also found in: Dictionary, Medical, Legal, Financial, Encyclopedia, Wikipedia.
  • noun

Synonyms for agent

Synonyms for agent

that by which something is accomplished or some end achieved

a person who secretly observes others to obtain information

Synonyms for agent

any agent or representative of a federal agency or bureau

the semantic role of the animate entity that instigates or causes the happening denoted by the verb in the clause

References in periodicals archive ?
an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with cardiac microvascular insufficiency and myocardial ischemia due to advanced coronary artery disease (www.
The Generx product candidate[Ad5-FGF-4] alferminogene tadenovec, is an angiogenic gene therapy that is being developed as a pioneering treatment for Cardiac Microvascular Insufficiency or CMI in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to advanced coronary artery disease (CAD).
Collateral has assembled a broad portfolio of therapeutic genes for use in the development of angiogenic gene therapy products.
The Generx angiogenic gene therapy product candidate is designed to stimulate the body's natural healing response to ischemic coronary artery disease by promoting the growth of microvascular circulation (collateral network) in the heart in order to enhance blood flow (cardiac perfusion).
In March 2000, the company reported positive results from a double-blind, placebo-controlled Phase 1/2 clinical trial of its lead product candidate, GENERX, a non-surgical angiogenic gene therapy for the treatment of angina due to coronary artery disease, that utilizes the FGF-4 gene licensed from NYU.
angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention.
alferminogene tadenovec, Ad5FGF-4) is a Phase 3 angiogenic gene therapy for the potential treatment of patients with Cardiac Microvascular Insufficiency or CMI due to advanced coronary artery disease.
In January 2014, the Company reported encouraging initial clinical study findings from its ASPIRE international Phase 3 registration clinical study, which is designed to confirm the continued safety and effectiveness from four previously completed clinical studies of Generx as an interventional cardiology angiogenic gene therapy for the potential treatment of cardiac microvascular insufficiency, a condition that leads to myocardial ischemia due to advanced coronary artery disease http://www.
In January 2014, Cardium reported encouraging initial clinical pilot study findings from its ASPIRE international Phase 3 registration clinical study, which is designed to confirm the continued safety and effectiveness from four previously completed clinical studies of Generx as an interventional cardiology angiogenic gene therapy for the potential treatment of cardiac microvascular insufficiency, a condition that leads to myocardial ischemia due to advanced coronary artery disease http://www.